{
  "docId": "019dd923-5eff-723e-9be5-b94899e664a4",
  "docSlug": "36e1d05af578f830",
  "documentTitle": "2025 Investor Day 2",
  "authorId": "Veeva",
  "authorName": "Veeva",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 36,
  "pageCount": 51,
  "prevPage": 35,
  "nextPage": 37,
  "slideType": "segmentation",
  "function": "decompose_segments",
  "density": "balanced",
  "nDataPoints": 5,
  "notes": "The chart visualizes revenue concentration, highlighting the dominance of the Biopharma segment.",
  "elementsJson": [
    "headline_text",
    "bar_chart_horizontal",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5eff-723e-9be5-b94899e664a4/36",
  "deckHref": "/decks/019dd923-5eff-723e-9be5-b94899e664a4",
  "deckJsonHref": "/decks/019dd923-5eff-723e-9be5-b94899e664a4.json",
  "deckAnchorHref": "/decks/019dd923-5eff-723e-9be5-b94899e664a4#slide-36",
  "components": [
    {
      "bbox": {
        "h": 0.21,
        "w": 0.76,
        "x": 0.118,
        "y": 0.398
      },
      "kind": "chart",
      "text": "Biopharma 92%, MedTech 5%, Other Industries 3%. Biopharma breakdown: Top 20 ~50%, Enterprise ~15%, SMB ~35%.",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82b7c660-96da-4cea-9dab-7ab2afd14c05",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.04,
        "x": 0.94,
        "y": 0.95
      },
      "kind": "image",
      "text": "Veeva",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "201f9832-017e-4066-b8b3-5c095d2a725a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Revenue mix: 92%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-880d-72b9-894a-e3d749208ae2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.35,
        "x": 0.038,
        "y": 0.92
      },
      "kind": "subtitle",
      "text": "Approximates Q2'26 revenue mix. Enterprise includes top 6 CROs, with the remainder of CRO revenues included in SMB",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f7a15af5-99ff-4181-8d43-608a8b2bce00",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.78,
        "x": 0.11,
        "y": 0.13
      },
      "kind": "title",
      "text": "Strong Base Within Primary Biopharma Segment",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a91fb001-9144-4f6e-ad2b-06ee24bb4730",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "market-segmentation-pyramid",
      "slug": null,
      "matchId": "9f0d7463-830c-4720-af67-cac359162e99",
      "evidence": "Decomposition of revenue by industry and customer size segments.",
      "confidence": 0.7
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}